Basic information
- Name:
Cisplatin
- CAS No.:
15663-27-1
- Molecular Structure:
- Formula:
- Cl2H6N2Pt
- Synonyms:
- Neoplatin;Platosin;cis-dichlorodi-ammine platinum(ii);cis-Diammineplatinum(II) dichloride;cis-Dichlorodiamminoplatinum(II);CPDD;cisPt(II);cis-Platinum(II) diaminodichloride;Platinum(II), diamminedichloro-, cis-;Biocisplatinum;Cisplatyl;DDP (antitumor agent);Cisplatinum;azane; platinum(+2) cation; dichloride;
Other Products
- Titanium DioxideCarbon black Glutathione Adenosine Cable pulling lubricant
- 52482-62-98-butan-2-yl-1,3,7-trimethyl-purine-2,6-dione
- 5731-10-24'-Fluorobiphenyl-4-carboxylic acid
- 10128-91-3Methyl 2-oxo-1,2-dihydro-3-pyridinecarboxylate
- 39802-78-32'-Chlorobiphenyl-4-carbaldehyde
- 111174-59-5Alcohols, C8-16, reaction products with phosphorus oxide (P2O5)
- 7554-28-1D-(+)-Malic acid diethyl ester
- 7682-14-6N-ACETYL-DL-2-AMINO-N-BUTYRIC ACID
- 114176-54-4ethyl (NZ)-N-[[2-(6-chloropyrazin-2-yl)hydrazinyl]methylidene]carbamate
- 15833-00-82-(2-Aminophenyl)propan-2-ol
- 1550-27-21-chloro-2-nitro-4-(trifluoromethylsulfonyl)benzene
- 76-46-02-(2-Hex-1-ynylcyclohexyl)isoindole-1,3-Dione
- 31738-10-06,16B-DIMETHYL-20-OXO-11B,17A,21-TRIOL-2-(P-FLUOROPHENYL)PREGNA-4,6-DIENO-(3,2-
- 697-37-01-prop-1-ynylcyclohexan-1-ol
- 175135-19-05-morpholin-4-yl-2-nitro-phenolate
- 22255-10-3[(3S,6aR,6bS,8aR,11R,12S,12aS,14aS,14bS)-4,4,6a,6b,8a,11,12,14b-octamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,14,14a-tetradecahydro-1H-picen-3-yl] hexadecanoate
- Refine Suppliers
- Do you want your product ranking ahead? Know what is 'Top Seller'!
- Supplier Location:
China (Mainland)(52)
India(8)
United States(5)
Hong Kong(1)
Singapore(1)
Switzerland(1)
United Kingdom(1)
- Business Type:
- Importer/Exporter(45)Lab/Research institutions(8)Manufacturers(2)
- Certificates:
- ISO(2)Production License(2)
Please post your buying leads,so that our qualified suppliers
will soon contact you!
*Required Fields
Chemistry
Molecular Structure of Cisplatin (CAS NO.15663-27-1):
.png)
IUPAC Name: azanide; dichloroplatinum(2+)
Empirical Formula: H6Cl2N2Pt
Molecular Weight: 300.051
Density: 3,7 g/cm3
Melting point: 340 °C
Form: crystalline
Color: yellow
Water Solubility: <0.1 g/100 mL at 19 ºC
Merck: 14,2317
Stability: Stable. Incompatible with oxidizing agents, aluminium, antioxidants
InChI
InChI=1/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
Smiles
[Pt+2]([NH3])([Cl-])([Cl-])[NH3]
EINECS: 239-733-8
Product Categories: Pharmaceutical material and intermeidates; Active Pharmaceutical Ingredients; Antitumors for Research and Experimental Use; Biochemistry; Classes of Metal Compounds; Pt (Platinum) Compounds; Transition Metal Compounds; Intermediates & Fine Chemicals; Pharmaceuticals; Caspases/Apoptosis; anti cancer
History
The compound cis-PtCl2(NH3)2 was first described by M. Peyrone in 1845. Approved for clinical use by the United States Food and Drug Administration (FDA) in 1978.
Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| child | TDLo | unreported | 19200ug/kg/12 (19.2mg/kg) | SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR | Journal of Pediatrics. Vol. 103, Pg. 1006, 1983. |
| dog | LDLo | intravenous | 2500ug/kg (2.5mg/kg) | GASTROINTESTINAL: OTHER CHANGES KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" BLOOD: METHEMOGLOBINEMIA-CARBOXYHEMOGLOBIN | Toxicology and Applied Pharmacology. Vol. 25, Pg. 230, 1973. |
| frog | LD50 | parenteral | 17mg/kg (17mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" | Journal of Comparative Pathology. Vol. 103, Pg. 387, 1990. |
| guinea pig | LD50 | intraperitoneal | 9700ug/kg (9.7mg/kg) | SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR | Toxicology and Applied Pharmacology. Vol. 33, Pg. 320, 1975. |
| human | TDLo | intradermal | 40ng/kg (0.00004mg/kg) | SKIN AND APPENDAGES (SKIN): PRIMARY IRRITATION: AFTER TOPICAL EXPOSURE SKIN AND APPENDAGES (SKIN): CORROSIVE: AFTER TOPICAL EXPOSURE | Cancer Research. Vol. 35, Pg. 2766, 1975. |
| human | TDLo | intravenous | 500ug/kg/13D- (0.5mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: RENAL FUNCTION TESTS DEPRESSED BLOOD: OTHER CHANGES | Cancer Treatment Reports. Vol. 62, Pg. 693, 1978. |
| human | TDLo | intravenous | 1500ug/kg/6D- (1.5mg/kg) | SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR KIDNEY, URETER, AND BLADDER: RENAL FUNCTION TESTS DEPRESSED BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE | Cancer Chemotherapy Reports, Part 1. Vol. 57, Pg. 191, 1973. |
| human | TDLo | intravenous | 2500ug/kg (2.5mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" GASTROINTESTINAL: NAUSEA OR VOMITING KIDNEY, URETER, AND BLADDER: RENAL FUNCTION TESTS DEPRESSED | Cancer Chemotherapy Reports, Part 1. Vol. 59, Pg. 647, 1975. |
| human | TDLo | intravenous | 72mg/kg/25D-I (72mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING | Cancer Treatment Reports. Vol. 62, Pg. 1591, 1978. |
| mammal (species unspecified) | LDLo | intravenous | 8mg/kg (8mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 28(4), Pg. 285, 2000. |
| man | TDLo | intravenous | 2140ug/kg/5D- (2.14mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" | Japanese Journal of Medicine. Vol. 23, Pg. 283, 1984. |
| man | TDLo | parenteral | 2140ug/kg/5D- (2.14mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" | Nippon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine. Vol. 72, Pg. 1426, 1983. |
| monkey | LDLo | intravenous | 250ug/kg (0.25mg/kg) | Cancer Vol. 33, Pg. 1219, 1974. | |
| mouse | LD50 | intramuscular | 17900ug/kg (17.9mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: NORMOCYTIC ANEMIA | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 723, 1982. |
| mouse | LD50 | intraperitoneal | 6600ug/kg (6.6mg/kg) | Journal of Medicinal Chemistry. Vol. 34, Pg. 414, 1991. | |
| mouse | LD50 | intravenous | 11mg/kg (11mg/kg) | Archives of Toxicology, Supplement. Vol. 7, Pg. 90, 1984. | |
| mouse | LD50 | oral | 32700ug/kg (32.7mg/kg) | LUNGS, THORAX, OR RESPIRATION: CYANOSIS GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED | Kiso to Rinsho. Clinical Report. Vol. 15, Pg. 5669, 1981. |
| mouse | LD50 | parenteral | 22mg/kg (22mg/kg) | International Journal of Radiation Oncology, Biology, Physics. Vol. 5, Pg. 1417, 1979. | |
| mouse | LD50 | subcutaneous | 13mg/kg (13mg/kg) | Journal de Pharmacie de Belgique. Vol. 41, Pg. 286, 1986. | |
| mouse | LD50 | unreported | 10900ug/kg (10.9mg/kg) | Gan to Kagaku Ryoho. Cancer and Chemotherapy. Vol. 13, Pg. 280, 1986. | |
| rat | LD | unreported | > 5mg/kg (5mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" | Journal of Toxicological Sciences. Vol. 24, Pg. 337, 1999. |
| rat | LD50 | intramuscular | 9200ug/kg (9.2mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: NORMOCYTIC ANEMIA | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 723, 1982. |
| rat | LD50 | intraperitoneal | 6400ug/kg (6.4mg/kg) | Journal of Toxicological Sciences. Vol. 18, Pg. 31, 1993. | |
| rat | LD50 | intravenous | 8mg/kg (8mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | JNCI, Journal of the National Cancer Institute. Vol. 67, Pg. 201, 1981. |
| rat | LD50 | oral | 25800ug/kg (25.8mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: NORMOCYTIC ANEMIA | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 723, 1982. |
| rat | LD50 | subcutaneous | 8100ug/kg (8.1mg/kg) | LUNGS, THORAX, OR RESPIRATION: CYANOSIS GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED | Kiso to Rinsho. Clinical Report. Vol. 15, Pg. 5669, 1981. |
Safety Profile
Hazard Codes of Cisplatin (CAS NO.15663-27-1): 
T
Risk Statements: 45-25-41-60-46-42/43-36/37/38
R45:May cause cancer.
R25 :Toxic if swallowed.
R41:Risk of serious damage to the eyes.
R60:May impair fertility.
R46:May cause heritable genetic damage.
R42/43:May cause sensitization by inhalation and skin contact.
R36/37/38:Irritating to eyes, respiratory system and skin.
Safety Statements: 53-26-39-45-99-36/37/39-22
S53:Avoid exposure - obtain special instructions before use.
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S39:Wear eye / face protection.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.
S22:Do not breathe dust.
RIDADR: UN 3288 6.1/PG 2
WGK Germany: 3
RTECS: TP2455000
F: 10-21
HazardClass: 6.1(a)
PackingGroup: II
Specification
Butenafine HCl , with CAS number of 15663-27-1, can be called Cisplatin;cis-Platinous diamine dichloroplatin ; cis-Diamminedichloroplatinum(II) ; cis-Platinous diaminodichloride ; cis-Platinum diamminedichloride ; cis-diamminediChlorideplatinum ; Platinum, diamminedichloro-, cis- ; cis-Platin ; Platinum diamminodichloride ; Platidiam ; cis Diamminedichloroplatinum ; Platiblastin ; cis-Dichlorodiammineplatinum ; cis-Dichlorodiamine platinum ; Cisplatino ; cis-Platinum(II) diamine dichloride ; Cisplatyl ; (SP-4-2)-diamminedichloroplatinum ; Platinum(II), diamminedichloro-, cis- ; cis-Dichlorodiamminoplatinum(II) ; cis-dichlorodi-ammine platinum(ii) ; azane; platinum(+2) cation; dichloride . It is an orange-yellow to deep yellow solid or powder, can be used as an antineoplastic, Cisplatin (CAS NO.15663-27-1) combine with DNA, causing cross-linking, thereby undermining the function of DNA and inhibition of cell mitosis, as a cell non-specific drugs. The broader spectrum of anti-tumor products, for head and neck squamous cell carcinoma, ovarian carcinoma, embryonic carcinoma cells, sperm immunogenicity cell tumor, lung cancer, thyroid cancer, lymphosarcoma and reticular cell sarcoma. Cisplatin is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas , lymphomas and germ cell tumors. Cisplatin is administered intravenously as short-term infusion in physiological saline for treatment of solid malignacies.
- About us
- |
- Payment
- |
- Contact us
- |
- Links
- |
- Help Center
- |
- Disclaimer
- |
- Add to favorite
- | SiteMap
- |
- Product SiteMap
- |
- Manufacturers
- |
- Suppliers
©2008 LookChem.com,License:ICP NO.：Zhejiang10014259
[Hangzhou]86-571-85317600,85317603,85317620